• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Catherine Shaffer

Articles by Catherine Shaffer

Prothena Prices $130M Offering; Janssen to Sell All Holdings

Oct. 4, 2013
By Catherine Shaffer
A public offering of about 5.9 million shares at $22 per share will bring in about $70.8 million in net proceeds for Prothena Corp. plc.
Read More

Myriad, Biomarin Team Up for BRCA Testing in Phase III

Oct. 3, 2013
By Catherine Shaffer
Myriad Genetics Inc. will return for a repeat engagement of its Phase I collaboration with Biomarin Pharmaceuticals Inc. to deliver BRAC testing for Biomarin’s pivotal Phase III trials of BMN 673. BMN 673 is an oral poly ADP-ribose polymerase (PARP) inhibitor designed to kill BRCA-deficient cancer cells.
Read More

Antibiotic Trial to Combine I.V. and Oral Dosing

Oct. 2, 2013
By Catherine Shaffer
Tetraphase Pharmaceuticals Inc., of Watertown, Mass., shared the design of its planned Phase III trial of eravacycline for complicated urinary tract infections (cUTI), due to begin enrolling in late 2013.
Read More

Relypsa Joins IPO Rush With a $126.5M Filing

Oct. 1, 2013
By Catherine Shaffer
Riding high on recent positive Phase III data for its hyperkalemia candidate, Relypsa Inc. filed for a $126.5 million initial public offering (IPO) to ramp up commercial operations for launch of patiromer, which is designed to remove potassium in the colon.
Read More

Inotek Vision for Glaucoma Supported by $28M in Financing

Sep. 30, 2013
By Catherine Shaffer
Inotek Pharmaceuticals Corp., of Lexington, Mass., plans to apply $21 million in proceeds from a venture financing and $7 million in venture debt financing to advance its A1 subtype adenosine mimetic for glaucoma and ocular hypertension. The funds will allow it to begin a Phase II study of trabodenoson in combination with latanoprost in late 2013.
Read More

CureDuchenne Ventures Launches with $5M Commitment to Lexicon

Sep. 26, 2013
By Catherine Shaffer
People with Duchenne muscular dystrophy (DMD) have gained a powerful new ally in CureDuchenne Ventures, a nonprofit organization dedicated to funding drug discovery and development for the rare disease.
Read More

Merck to Move Forward with Oncothyreon Cancer Vaccine

Sep. 26, 2013
By Catherine Shaffer
An anxious wait for Oncothyreon Inc. has come to an end, as Merck KGaA announced it would continue development of tecemotide (formerly Stimuvax) following last year’s Phase III trial miss.
Read More

X-Chem Racks Up the Milestones in Its Astrazeneca Partnership

Sep. 25, 2013
By Catherine Shaffer
X-Chem Inc., of Waltham, Mass., said it achieved several milestones in a licensing agreement with Astrazeneca plc, of London, established in May 2012. That deal garnered the company an up-front payment and research funding, as well as discovery and clinical development milestones.
Read More

First Interim Analysis in 2Q14: Regado launches phase III trial testing first-in-class clotbuster

Sep. 24, 2013
By Catherine Shaffer

FDA Bestows SPA for Achaogen Antibiotic Trial

Sep. 24, 2013
By Catherine Shaffer
A Phase III trial of Achaogen Inc.’s plazomicin for serious multidrug-resistant gram-negative bacterial infections will be carried out through a special protocol assessment (SPA) under a new agreement with the FDA. The trial will assess safety and efficacy of the drug compared with colistin in patients with bloodstream infections and nosocomial pneumonia caused by carbapenem-resistant Enterobacteriaceae (CRE).
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 … 60 61 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 27, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe